Session » 5T089 ACR Abstract: RA–Treatments IV: Strategy (2820–2825)
- 2:30PM-4:00PM
-
Abstract Number: 2823
Comparative Long-Term Effectiveness of Switching to Another Tumour Necrosis Factor Antagonists, Tocilizumab or Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to a First-Line TNF Inhibitor
- 2:30PM-4:00PM
-
Abstract Number: 2821
Dose Tapering and Discontinuation of Biological Therapy in Rheumatoid Arthritis Patients in Routine Care – 2-Year Outcomes and Predictors
- 2:30PM-4:00PM
-
Abstract Number: 2824
On Tapering Therapy for RA Patients in Clinical Remission; Flare on Csdmards Predicted By Clinical Features and Musculoskeletal Ultrasound, Whereas T-Cell Abnormalities Predictive for b-DMARD Tapering
- 2:30PM-4:00PM
-
Abstract Number: 2825
Reduction of Antidrug Antibody Levels after Switching to Rituximab in Patients with Rheumatoid Arthritis with Previous Failure to Infliximab or Adalimumab
- 2:30PM-4:00PM
-
Abstract Number: 2822
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis